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Susan Lindquist and I had been trying
to intersect for an interview for about 5
years. Lindquist (Image 1), who is current-
ly on the faculty at MIT’s Whitehead
Institute, is well-known for her work on
protein chaperones and stress responses.
Her interests grew out of thesis research in
the early 1970s in Matt Meselson’s lab,
where she developed a strategy to study
the heat-shock response in cultured cells of
Drosophila, an approach that complement-
ed observations on transcriptional puffs on
polytene chromosomes. In the subsequent
20 years at the University of Chicago,
Susan continued to pursue the biochemi-
cal and cell-biological properties of heat-
shock proteins (HSPs), which assist with a
host of protein-folding problems. In 1994,
she found herself immersed in a mystery of
non-Mendelian inheritance when Yury
Chernoff called to say that one such
protein, Hsp104, controlled the [PSI+]
phenotype. This swept her from stress
tolerance to prions and then on to
problems of protein folding in cancer
and neurodegeneration. I was eager to
understand Susan’s work and gain her
perspective on how chaperones and re-
modeling proteins promote rapid evolu-
tionary change in response to environ-
mental stresses, a neo-Lamarkian view of
biology.
And thus it was that during a cold but
sunny January in San Francisco, as I
watched the nightly reports of snowstorms
in the Northeast, I impulsively decided now
was the time to visit Susan: I had to be
part of the climatic happening. Having
grown up in Pennsylvania where snow-day
school closures were cherished, and having
lived at MIT during the great blizzard of
1978, I diagnosed myself with snowdrift-
withdrawal and sought a hit of the fluffy
stuff. I managed to fly into and out of
Boston easily, intercalating my travel
between a series of storms, yet immersing
myself in flurries and new-fallen blankets
while I was there.
We started our morning interview a bit
later than planned, as traffic in Boston was
snarled, and Susan began by showing me
the picture of her with President Barack
Obama in the White House, where she
was recently awarded the National Medal
of Science.
Gitschier: I watched the ceremony
online!
Lindquist: You did? How sweet of
you. It was unbelievable.
Gitschier: Let’s start with that.
Lindquist: Right before this picture
was taken I shook his hand and said, ‘‘I’m
so glad I’m getting this from you and not
the other guy.’’
Gitschier: And what did he say?
Lindquist: He smiled. After the cere-
mony, we had some back and forth banter
and it was charming. I said that I brought
good wishes from all the scientists I knew,
and said that we were really grateful for all
that he was doing not just for science, but
for the world. And he said, ‘‘Yeah, I poll
well with scientists.’’
Gitschier: Did you just want to throw
your arms around him?
Lindquist: I did! I’ve never been
struck like that before. I really felt like I
was in the presence of a great man.
Gitschier: Had you known him at the
University of Chicago?
Lindquist: No. I have a good friend
who played basketball with him, though!
Gitschier: I know that for the human
geneticists in Chicago, it was Obama fever
during the campaign and election. I must
say the award ceremony was so moving.
Lindquist: I thought the remarks he
made about how science matters at the
highest levels were important. But his
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fair winners from all over the country to
the White House really got me. Can you
imagine the thrill of the lifetime it would
be for a kid like that? And he loved it. He
was chatting with them all, wanted to
know what they were doing.
Gitschier: It was a big day for prions;
I noticed that [Stan] Prusiner also won the
Medal.
Lindquist: Yes. My citation was
mostly for other things, but the role of
prions in biology is beginning to explode.
Prusiner, Eric Kandel, and I are all going
to be speaking at a symposium in honor of
Oliver Smithies.
Gitschier: Let’s talk about the Aplysia
work with Eric Kandel. You and he had a
paper together on CPEB [cytoplasmic
polyadenylation element binding protein].
You guys had postulated a few years ago
that an amyloid form of this protein
aggregated in synapses and could be
important for solidifying neuronal connec-
tions. Has that gone anywhere?
Lindquist: We have a paper in press
in PNAS where we show that CPEB really
does function as a prion. Not proved in
neurons yet, but we assembled the fibers in
vitro with purified recombinant protein,
took the cell walls off of yeast, and
transformed them from the inactive CPEB
state to the active state. So the prion
conformation alone switches the protein to
a stable active state. It is a cellular
mechanism for memory.
Gitschier: When you say ‘‘active
state’’, what do you mean?
Lindquist: For many of the prions that
have been looked at, when they convert to
self-templating amyloids, they lose their
normal activity. For example, the first
prion we worked on is called [PSI+]; it is
the amyloid form of SUP35, a translation
termination factor. Only a small section of
the protein does the aggregation.
Gitschier: And the rest of it is
dangling out.
Lindquist: Right. And when it is
converted to the amyloid, SUP35 is
sequestered from the ribosome, so now
ribosomes don’t terminate [translation]
when they should. They read through
stop codons. But you could imagine the
amyloid assembly, with its functional
domain dangling out, could also provide
a scaffold—a high local concentration of
that subunit—that could recruit other
factors that need to function with it.
Gitschier: Let’s talk about the use of
the word prion, which was originally
coined for a very specific situation in
infectious neurodegenerative diseases like
scrapie, mad cow disease, and Creutzfeld-
Jacob disease. So using the term prion for
these other situations—how far are we
going to go with this? How was this word
originally adapted for yeast?
Lindquist: So that was Reid Wick-
ner’s terminology, and he based it upon
the thought that these heritable pheno-
types were due to some sort of a self-
perpetuating state that was based on
protein.
Gitschier: This is his 1994 Science
paper where he first described [URE3]
as a prion and that it was actually an
altered protein product of the URE2 gene.
Lindquist: Yeah. It could have been a
self-perpetuating auto-phosphorylation,
protease-activation self-degradation, it
could have been all sorts of things.
Gitschier: Oh really? You mean he
appropriated that term for all of those
uses?
Lindquist: Yes. In fact, he’s published
a paper in which a self-perpetuating
change in protein cleavage causes a
heritable change in phenotype. It’s a very
clever paper, I think, and not properly
appreciated.
But, anyway we found that SUP35 is a
self-templating amyloid. The soluble pro-
tein can just sit there for hours and doesn’t
do anything, but if you add just a
smidgeon of the amyloid form, it can
template the soluble protein into fibers
very efficiently. That sequesters it out of
solution. So that’s what gives it this bi-
stable state. That is, it can exist stably as a
non-prion or as a prion.
Gitschier: So presumably this is a
highly cooperative kind of thing.
Lindquist: Yes. It turns out to be
surprisingly like the PrP protein.
I think that this is where the more we
learn about stuff it’s not as easy to use
simple labels. The same thing has hap-
pened with chaperones. The chaperone’s
initial definition was nice and simple:
proteins that bind to other proteins in
the immature state, where they are prone
to making inappropriate liaisons with
other proteins, and it prevents them from
doing that. And then when the protein is
matured it leaves them alone. Beautiful
definition that is really evocative of its
function, but now we know that a lot of
proteins are stably complexed with chap-
erones and chaperones can even be part of
the functional state. Definitions blur be-
cause biology doesn’t fit into little boxes.
And people get into very big arguments
about whether or not you should call this a
prion or that a prion.
Gitschier: Let’s talk about curing
prion infections with guanidine hydrochlo-
ride. You had a paper that suggested that
it wasn’t doing it directly, by reconfiguring
the prion, as I would have expected, but
rather that it was affecting the chaperones.
Lindquist: That’s how we got into
this. We were actually working on it well
before Reid Wickner’s paper came out.
Gitschier: Tell me about that.
Lindquist: So, I’ve been working on
heat-shock proteins for a long time. All the
major proteins that come up after heat
shock have to do with the protein-folding
problem, handling it in different ways,
mainly as chaperones and protein-remod-
eling factors. The two that we’ve worked
on the most are Hsp90, which is a protein
chaperone, and Hsp104, which is a
protein disaggregase.
So, the reason that I got into the prion
business was that other folks had shown
there was a weird genetic factor that had
behaved in a lot of weird ways.
Gitschier: You’re talking about
SUP35 gene product and the [PSI+]
phenotype?
Lindquist: Yeah.
Gitschier: OK, so let’s back up and
talk about Brian Cox and all of his work
on [PSI+].
Lindquist: Brian Cox is wonderful.
He is an unsung hero.
Gitschier: He’s got papers back to
1965 in Heredity—talking about [PSI+]
phenotype, about how there is a heritable
but non-Mendelian determinant that sup-
presses certain auxotrophic mutants in
yeast.
Lindquist: And I talk about Brian,
especially to students, because Brian had a
whole series of perplexing observations
and he published them. He didn’t have to
understand the molecular mechanism, and
he didn’t have to publish them in Nature,
Cell,o rScience, and it was good quality,
rigorous, beautiful work on a difficult
problem. We have a tendency, and this
happens in my lab all the time, to think
that unless we really understand some-
thing, we don’t publish it.
I think it is a shame, because biology is
full of odd observations and it’s the odd
observations that can wind up pulling
together two or three things from different
places, and then suddenly you understand
it. But in any one line of research, you
might not be able to understand it.
So Brian Cox set up all of the basics of
this. And there were some Russian groups
too, and together they set up all the
paradigms that then, when you under-
stand the biochemistry, make it completely
easy to understand.
Gitschier: Did you know Brian Cox
prior to 1994?
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give a talk. There were some concurrent
sessions at a genetics meeting, and I
remember saying I was going to go to his
talk because it sounded really interesting,
and I remember a group of friends trying
to dissuade me from going to the talk.
They said, ‘‘Oh God, he’s been going on
about that forever. Such a weird thing,
who wants to hear about that?’’
But I was always fascinated by weird
things, so I figured I’d go to his talk. I also
went to a talk that Sue Liebman gave. All
these people had shown that the inheri-
tance of that weird phenotype obeyed very
specific rules, they were just different from
the normal rules of phenotypes based on
DNA mutations.
Gitschier: Before 1994.
Lindquist: Yeah. And Reid had
certainly been thinking about these data
when he showed similar things for
[URE3], leading to the prion hypothesis.
We got into this because Yury Chernoff,
who was working on [PSI+], called me
and said, ‘‘I’ve been trying to figure out
what’s controlling the inheritance of this
thing and I just did a genetic screen and
the only thing that I’ve come up with that
seems to affect it very strongly is Hsp104.
Do you know what it [Hsp104] does?’’
The reason he called me was that we
had been working on these heat-shock
proteins and published a nice paper that
showed Hsp104 was responsible for
thermo-tolerance in yeast. But we had
not yet published its molecular mecha-
nism. In fact, I am at my desk, sitting there
quite literally with this paper that had just
been rejected from Nature. And I said, ‘‘Yes
I do know what it does, it takes apart
protein aggregates, but no one will believe
me.’’ Every one of the reviewers had said
that it was ridiculous, that it couldn’t
possibly be true.
Gitschier: So the dogma was that
chaperones help you fold initially, but they
won’t disaggregate.
Lindquist: Yes. And I had a hard time
even getting people in my lab to consider
the possibility, but once we did the
experiments it was clear that that was
what it was doing. So, anyway, if a cell is
defective in Hsp104, it never gets rid of
heat-induced aggregates.
Gitschier: So are these aggregates
prions?
Lindquist: They can be! You are
anticipating the answer. We found that if
you knock out Hsp104, you lose the
phenotype caused by Sup35, and if you
overexpress it, you also lose the pheno-
type.
We knew that Hsp104 controlled pro-
tein aggregation, so we asked whether
there was a difference in the physical state
of SUP35 protein in [PSI-] and [PSI+]
cells. It was an obvious question. And the
answer was ‘‘Yes!’’ SUP35 forms large
aggregates in [PSI+] cells and Hsp104 gets
rid of them.
Gitschier: Is that part of this Chernoff
paper, or later?
Lindquist: It’s later. In Yury’s paper
the cool thing was that just transient
expression of Hsp104 was sufficient to
cure it. So here we have two new things:
transient overexpression of SUP35 gives a
heritable new phenotype, and the tran-
sient overexpression of Hsp104, a protein
disaggregase, switches cells back heritably
to the other phenotype.
Everybody thinks of prions as being
bad, scary things. But in yeast cells this
prion domain has been conserved for
about 800 million years. You can take
the prion domain off SUP35 and substi-
tute the corresponding sequence from
Candida albicans, and not only does it form
the prion, it is also controlled by Hsp104.
So why might they have this? Without
enough soluble SUP35, the ribosome is
going to be reading through lots of stop
codons. It could be activating pseudogenes
that have a stop codon. It could add
additional amino acids and alter the
folding of the protein. Or change messen-
ger RNA stability because where the
ribosome is on the message can cause the
message to be stable or unstable.
Gitschier: So you’re suggesting it’s
kind of like an SOS thing.
Lindquist: Sort of. You might expect
to have a bunch of new phenotypes with
[PSI+], which might be different in
different strains because the stuff that is
downstream of stop codons is not highly
conserved. So there will be different
consequences when you read beyond the
stop codon in different strains. We think it
provides a survival advantage through
phenotypic variation. Many of the pheno-
types will be bad, and so what? Typically
one in a million cells switches to the prion.
If they die, no harm done. But if [PSI+]
happens to provide a good phenotype in a
bad environment, a few cells in that colony
may survive and their genome will survive.
And that could also lead to the evolution
of new traits with a few additional
mutations. So our idea is that this is a
bet-hedging strategy for a few cells in the
colony to start placing different bets in
terms of what phenotypes they want to
have.
And what’s cool about this is that it
allows the organism to acquire a complex
trait in a single step. Because you read
through lots of stop codons some will be
good, some will be bad, but it is combi-
natorial.
So the logic of this is that the rate at
which cells switch into the prion state
really should increase with stress. If things
aren’t so good, they may want to try that
bet—flip into trying a new phenotype
more often. And we tested that, and that
happens. We have a lot of data on this: lots
of different stresses will cause the cells to
switch into a prion state, or if you’re
already in the prion state, they’ll switch
away from it more frequently. And it’s all
tied up with protein homeostasis. So if the
cell is not well-adapted to its environment,
it’s more likely to have a protein-folding
problem, it’s more likely a protein will
switch to the prion, and it’s more likely to
induce Hsp104 and switch out of the prion
state. Instead of one in a million cells
switching, one in ten thousand do.
Gitschier: Of course, this is all based
on SUP35 prion formation—allowing
ribosomes to read through stop codons.
Does Drosophila have this prion domain on
SUP35, for example?
Lindquist: No, it’s just in fungi. But in
my view this switch is part of early
evolution and early life, because many
different proteins can form amyloid states.
We did a screen for new prions: we’ve now
found 25 new ones in yeast.
Gitschier: You screened for it in what
way—bioinformatics?
Lindquist: Bioinformatics and then
testing. We had 200 candidates, looking
for these weird domains, we tested 100 of
them, and 25 are prions. They create all
kinds of interesting phenotypes.
Gitschier: Enough for 25 more grad-
uate students!
Lindquist: Absolutely. One causes the
cells to come together and form biofilms,
for example. The proteins are enriched in
RNA-binding and DNA-binding and sig-
nal transducers. So they allow the cell to
try out different things and it will be stable
and heritable. So we think we have this
whole host of capacitors for evolutionary
change.
Gitschier: Now when you say the
word ‘‘capacitors’’, what do you mean?
Lindquist: We first used the term for
Hsp90. I think that will be even bigger
than prions.
Gitschier: OK, glad I asked.
Lindquist: What we meant by that is
that Hsp90 provides a way for organisms
to accumulate a lot of genetic variation
that lies hidden in their genomes and then,
under conditions of stress, they release that
variation and they can acquire new traits.
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can cause inheritance of new phenotypes.
Both are Lamarckian mechanisms: La-
marck said that environment could cause
the inheritance of a new trait. It does!
Prions do, so does Hsp90.
So the cells are storing genetic variation,
like an electrical capacitor stores charge,
and there are mechanisms for releasing it
suddenly and in combinatorial fashion.
Gitschier: I understand the metaphor
for prions, but how does it relate to
Hsp90? I take it that Hsp90 is a chaper-
one?
Lindquist: Yes, not a remodeling
factor like Hsp104.
We were studying Hsp90 in yeast, way
back when it first became possible to
knock-out a gene in yeast. We found that
it’s a very abundant protein, but cells
normally need only a little bit of it. But
they do need all of it when they are
stressed. So it’s acting as a protein-folding
buffer—excess folding capacity that gets
used up with stress. And that is when
interesting things happen—with environ-
mental stress.
Hsp90 has a very interesting set of client
proteins. It was found complexed with
steroid hormone receptors as well as
oncogenic kinases—but inactive receptors
and kinases. So it was postulated that
Hsp90 is a protein repressor. And this was
coming out just when we are sitting there
with genetically modified yeast with dif-
ferent levels of Hsp90. So we said OK,
let’s use our yeast cells as a ‘‘living test
tube’’ and put these other proteins in
there. If Hsp90 is a repressor, if you
reduce levels, the proteins should become
more active. And the opposite happened.
For example, Src kinase normally folds
back on itself and self-inhibits. And the
mutations that activate it knock out that
ability to fold back on itself; Src opens up
and it’s highly unstable. Hsp90 comes
along and says, ‘‘Let me save you—you
are just the kind of protein I want to bind
to!’’ And while Src’s bound to Hsp90 it is
inactive, but what Hsp90 is really trying to
do is helping it to fold, stabilize it, and get
it to the membrane so that it can then be
active. So this buffer is enabling the
mutant kinase to create an immediate
new phenotype. This is sort of the opposite
of Hsp90’s role as a buffer that hides traits.
In this case the excess folding buffer
potentiates the effects of mutations imme-
diately.
Hsp90 is involved in folding all kinds of
meta-stable proteins—kinases, transciption
factors, steroid hormone receptors—that
are not meant to be fully folded until they
get a signal. Imagine that you start to
accumulate some mutations. Hsp90 could
hidetheireffectsbylettingproteinscontinue
to fold. Then when you reduce the buffer,
you might create new phenotypes in a
different way, because all hell breaks loose.
So in Drosophila, if you have Hsp90
heterozygote mutants, they are fine. But
we found that depending on the genetic
background, an individual fruit fly might
have a funny wing or leg or eye. That is,
reducing the Hsp90 folding buffer is
altering effects of genetic variation that
was hidden in the genome and allowing
new phenotypes to be manifested.
Then we found that by just increasing
the growth temperature, you also see the
same traits; by raising the temperature,
you create protein homeostasis stress and
deplete the Hsp90 buffer.
I know of no mutation that is as
pleiotropic as this—we saw hundreds of
different phenotypes. And these were
combinatorial phenotypes. The phenotype
depended on lots of different genetic
variants coming together to make a
phenotype.
And then we saw the same thing in
Arabidopsis—all kinds of phenotypes that
depended on Hsp90. Things growing like
a vine in agar, hairy roots, plants growing
upside-down, leaves coming out in differ-
ent ways. Lots of wild stuff. And we saw
most of the same phenotypes at higher
temperature. And so you are losing and
gaining phenotypes with environmental
stress.
In both Hsp90 and prions, the role of
protein homeostasis interfaces with envi-
ronmental stress to create new phenotypes.
And there are ways for both of those to
become heritable.
Gitschier: I don’t want to miss the
opportunity to ask you a few more things
before we close. How did you get inter-
ested in science?
Lindquist: I never expected to be-
come a biologist. My parents expected me
to become a housewife.
Gitschier: What did your parents do?
Lindquist: My mother was a house-
wife and my father was a carpenter/
contractor and then he became a tax
accountant after a financial setback.
Gitschier: What did your parents
make out of your wanting to go to
graduate school?
Lindquist: They thought it was nuts.
I’ll never forget my trip back home after
my first semester in graduate school. I had
a paper to finish. The night before New
Year’s Eve my parents came back around
midnight from a party and said, ‘‘Are you
still working? When are you going to settle
down?’’ I can still remember the exact
words, as though I was doing some kind of
ridiculous, frivolous thing. When I first
had kids they really expected me to quit,
too.
Gitschier: When was that?
Lindquist: I was lucky not to meet the
man I wanted to have children with until I
had tenure—Edward Buckbee. And he is
the most wonderful person in the world.
He has been an unbelievable partner to
me. I would not be where I am without
him.
Having children is a major intensifier in
your life—it’s not easy! And having the
tenure thing settled and having a little
more money at your disposal, those things
made having children a lot easier. I have a
lab full of people with children, and bless
them—I love having all these children in
my lab. But for me, I’m glad the
circumstances happened to be that I
waited a while.
You know, once my parents saw I was
successful and that I was doing something
that was worthwhile and important, they
became extraordinarily supportive. They
were wonderful and they were such loving
people. And my mother spent the last 3
years of her life living with us, and she was
so proud, it was so sweet and cute. She’d
brag about me to everyone.
Gitschier: She didn’t get to see you
win this big award.
Lindquist: [With tears brimming]
That was the one really sad part. It would
have been a life-long fulfillment if she
could have seen that.
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